In conclusion, our results show that IL-17A promotes NSCLC cell proliferation and increases PD-L1 expression in tumor cells by reducing PD-L1 degradation through inhibition of autophagy, creating a suppressive immune microenvironment. Here, IL17A is linked to non-small cell lung carcinoma.